Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Company Overview - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Group 2: Financial Guidance and Performance - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions showed lower than expected enrollment growth and increased morbidity rates in the majority of the states served by Centene [4]. Group 3: Stock Performance and Market Reaction - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report revealed lower than expected market growth and higher morbidity rates [5]. - Following this news, Centene's stock price plummeted by $22.87 per share, a decline of over 40%, from $56.65 on July 1, 2025, to $33.78 on July 2, 2025 [5].

NEW YORK, Aug. 26, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Centene Corporation (NYSE: CNC) between December 12, 2024 and June 30, 2025, both dates inclusive (the "Class Period"), of the important September 8, 2025 lead plaintiff deadline.So what: If you purchased Centene securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.What to ...

Core Viewpoint - Centene Corporation is facing a class action lawsuit due to allegations of misleading investors regarding its revenue outlook and growth prospects during the specified Class Period [1][4]. Group 1: Company Overview - Centene Corporation is a healthcare enterprise that provides integrated services to government-sponsored and commercial healthcare programs, focusing on underinsured and uninsured individuals [3]. Group 2: Allegations and Misrepresentation - The class action lawsuit claims that Centene misled investors by presenting false information about its projected revenue and growth, emphasizing strong enrollment rates and low morbidity levels [4]. - The complaint alleges that these representations were materially misleading, as they concealed adverse enrollment trends and worsening morbidity rates [5]. Group 3: Financial Impact and Guidance Revision - On July 1, 2025, Centene withdrew its 2025 guidance, revealing disappointing findings from its analysis of the Health Insurance Marketplace, with market growth across 22 states significantly below expectations [6]. - Following the guidance revision, Centene's earnings were adjusted to approximately $1.8 billion, or an adjusted diluted EPS of $2.75 [6]. - The announcement led to a decline in Centene's stock price by more than 40%, causing significant financial harm to investors [7].

LAS VEGAS, Aug. 26, 2025 /PRNewswire/ -- AcariaHealth, a leader in specialty pharmacy solutions and a Centene Corporation company (NYSE: CNC), is taking center stage at the 2025 Healthcare Advocate Summit (Sept. 2–5) in Las Vegas with a first-of-its-kind "Reimagine Access" Hackathon and two can't-miss expert sessions.Reimagine Access: A Hackathon for Healthcare AdvocatesTuesday, Sept. 2 | 1:00–3:30 PM PT | Florentine 1–11This dynamic, hands-on session brings together healthcare advocates, providers, and pha ...

Key Takeaways Centene's HBR rose 550 basis points in Q2 2025 on higher medical costs and premium reserve impacts.Rising outpatient use, specialty drug expenses, and Medicaid redeterminations strain Centenes earnings.Centene is tightening cost controls, boosting value-based care, and divesting assets to support efficiency.Centene Corporation (CNC) relies on its Health Benefit Ratio (HBR) as a measure of profitability. Because Medicaid and ACA marketplace plans generate thinner margins than commercial insuran ...

LOS ANGELES, Aug. 25, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to fcruz@frankcruzlaw.com. Hims ...

Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Financial Guidance and Performance - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions showed lower than expected enrollment growth and increased morbidity rates in the majority of the states Centene serves [4]. Stock Market Reaction - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report revealed lower than expected market growth and higher morbidity rates, leading to a significant stock price drop of $22.87 per share, or over 40%, from $56.65 to $33.78 [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Centene Corporation securities between December 12, 2024, and June 30, 2025, of the September 8, 2025, deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Centene securities during the specified class period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the court by September 8, 2025, to serve as lead plaintiff [2]. - The lawsuit alleges that Centene's management provided misleading information regarding the company's revenue guidance and earnings per share for the 2025 fiscal year, while concealing adverse facts about enrollment and morbidity rates [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [3].

Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Financial Guidance and Performance - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions showed lower than expected enrollment growth and increased morbidity rates in the majority of the states Centene serves [4]. Stock Market Reaction - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report revealed lower than expected market growth and higher morbidity rates, leading to a significant stock price drop of $22.87 per share, or over 40%, from $56.65 to $33.78 [5].

NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Centene Corporation ("Centene" or the "Company") (NYSE: CNC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Centene investors who were adversely affected by alleged securities fraud between December 12, 2024 and June 30, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/centene-corporation-lawsuit ...